Physician profile
Daniel M Katz
NPI 1316087042
$3,330.24
in general payments reported to CMS, 2019-2025
13 companies · $619 in 2025
The $619 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2021: $529 · 2022: $177 · 2023: $836 · 2024: $413 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,867.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,000.91 | 2021-2024 | Farxiga, Lokelma, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $961.61 | 2019-2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $219.08 | 2025 | Voquezna |
| Novo Nordisk INC | $207.68 | 2022-2025 | Ozempic |
| Lilly USA, LLC | $192.44 | 2022-2025 | Mounjaro |
| Abbott Laboratories | $183.79 | 2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2025 | |
| Amgen INC. | $118.73 | 2019-2025 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $95.29 | 2023 | Spravato |
| Teva Pharmaceuticals USA, INC. | $91.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $59.86 | 2019 | |
| Pfizer INC. | $54.44 | 2019-2025 | |
| Bardy Diagnostics, INC. | $19.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.